Therapeutic Antibodi - Agreement Terminated

RNS No 3330e
THERAPEUTIC ANTIBODIES INC
19th January 1999


G.D. SEARLE AGREEMENT

Therapeutic Antibodies Inc announces that an agreement to
develop an antibody for two G.D. Searle & Co. (Searle) products
was terminated today following Searle's decision to cease
development of its xemilofiban and orbofiban projects.

Therapeutic Antibodies signed the research agreement with
Searle, the pharmaceutical division of Monsanto Co., in May 1998
to identify and develop a 'rescue antibody' to these drugs.

Commenting on the news, Andrew Heath, chief executive officer of
Therapeutic Antibodies  said:

'Whilst Searle's decision to stop work on their underlying
projects is a disappointment, the alliance was a significant
endorsement of our platform technology and showed Therapeutic
Antibodies can work effectively, and to schedule, with a major
pharmaceutical company.

'Therapeutic Antibodies continues to investigate opportunities
for strategic partnerships and further collaboration.'

In the near term, Therapeutic Antibodies' top priority product
CroTAb, an antivenom to North American rattlesnakes, is under
active review by the FDA and is on schedule for marketing in mid
1999.  CroTAb is part of TAb's emergency medicine line,
comprised of CroTAb, DigiTAb and TriTAb, which is licensed in
the United States to Altana Inc, the US subsidiary of Altana AG.


Enquiries:

Andrew Heath  -  tel: [phone]
Chief Executive Officer, Therapeutic Antibodies Inc

Laura Frost  -  tel: [phone]
The Maitland Consultancy


END

MSCBLMLBLLJBMML